Pharma & Biotech

First reported Oct 31 2014 - Updated 10 hours ago - 7 reports

Gilead Sciences Receives New Coverage from Analysts at Edward Jones (GILD)

Edward Jones began coverage on shares of Gilead Sciences (NASDAQ:GILD) in a research note issued on Friday. The firm set a “hold” rating on the stock. Gilead Sciences (NASDAQ:GILD) traded down 2.14% on Friday, hitting $111.78. The stock had a trading ... [Published Mideast Time - 10 hours ago]
First reported 16 hours ago - Updated 12 hours ago - 6 reports

Biogen and Sobi Announce European Medicines Agency Validates ELOCTA™; BioLineRx Reports Results from Previous Phase 1/2 Trial for BCM (BL-1040)

Below is a look at some of the headlines for companies that made news in the healthcare sector on October 31, 2014.Biogen Idec (NASDAQ: BIIB) and Swedish Orphan Biovitrum AB (publ) (Sobi) (STO: SOBI) announced the European Medicines Agency (EMA) has validated ... [Published BioMedReports - 12 hours ago]
First reported Oct 31 2014 - Updated 13 hours ago - 4 reports

AbbVie Might Go Shopping Again Despite Shire Breakup, Say Company Execs

October 31, 2014By Riley McDermid , Breaking News Sr. EditorBiopharma giantAbbVie ( ABBV ) hasn’t been so burned by its recent failed acquisition of Irish firm Shire that it won’t keep looking for new targets, the company told analysts during ... [Published BioSpace - 17 hours ago]
First reported 21 hours ago - Updated 14 hours ago - 4 reports

Impax Labs to cut quarter of R&D jobs, merges some generic, branded operations

Impax Laboratories Inc. will cut 42 R&D jobs as it combines some functions of its generic and branded drug businesses.The Hayward company (NASDAQ: IPXL), which next week will lose the president of its generic business, Carole Ben-Maimon, to retirement, ... [Published San Francisco Business Times - 14 hours ago]
First reported Oct 31 2014 - Updated 20 hours ago - 5 reports

Specialised Therapeutics' Abraxane to be reimbursed via Australian PBS

Australian biopharma company Specialised Therapeutics is to have its Abraxane (nanoparticle albumin-bound paclitaxel) in combination with gemcitabine, reimbursed via the Pharmaceutical Benefits Scheme (PBS) for patients with metastatic pancreatic cancer ... [Published Pharma Letter - 20 hours ago]
First reported Oct 30 2014 - Updated 21 hours ago - 6 reports

Jobs saved as Boehringer Ingelheim finds Chinese buyer for U.S. plant set to close

UniTao will add about 130 positions to the 240 already thereShareToolsAbout 240 workers at a Boehringer Ingelheim complex in Virginia will have something special to celebrate this Thanksgiving: the prospect of keeping their jobs. Just weeks ahead of closing ... [Published FiercePharma - 21 hours ago]
First reported Oct 30 2014 - Updated 23 hours ago - 7 reports

Deal-Starved Perrigo Company In Exclusive Talks To Buy $5 Billion+ Omega Pharma NV

Perrigo Co. (PRGO) has entered exclusive talks to buy Omega Pharma NV after beating suitors including Sanofi, Actavis Plc and Boehringer Ingelheim GmbH, people with knowledge of the matter said.Perrigo may reach an agreement to buy Omega Pharma, a Belgian ... [Published BioSpace - 23 hours ago]
First reported Oct 30 2014 - Updated Oct 31 2014 - 19 reports

Update: AstraZeneca Wins FDA Approval For Xigduo XR, Shares Rise

Summary AstraZeneca announced today FDA approval for its diabetes combo pill Xigduo XR. I reiterate my bull thesis following the approval. As expected, AstraZeneca continues to enhance its growth prospects, thus supporting my thesis that it can thrive ... [Published Seeking Alpha - Oct 31 2014]
First reported Oct 30 2014 - Updated Oct 31 2014 - 17 reports

Smith & Nephew plc CEO Won't Comment On Sanofi CEO Job

October 30, 2014By Riley McDermid , Breaking News StaffThe chief executive of biotech Smith & Nephew ( SNN ) has declined to comment on speculation that he is interested in taking the recently-vacated top spot at French drugmaker Sanofi ... [Published BioSpace - Oct 30 2014]
First reported Oct 30 2014 - Updated Oct 31 2014 - 5 reports

Auxilium Pharmaceuticals Announces Third Quarter 2014 Financial Results

Auxilium Pharmaceuticals , Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, today announced financial results for the third quarter endingSeptember 30, 2014. The Company highlighted important corporate, commercial, regulatory ... [Published Citybizlist - Oct 31 2014]
First reported Oct 30 2014 - Updated Oct 31 2014 - 5 reports

Synageva BioPharma Reports Third Quarter 2014 Financial Results

/PRNewswire/ --  Synageva BioPharma Corp. (NASDAQ: GEVA), a biopharmaceutical company developing therapeutic products for rare disorders, announced today third quarter 2014 financial results, and provided other business updates.Click to Continue » ... [Published Rock Hill Herald - Oct 30 2014]
First reported Oct 30 2014 - Updated Oct 30 2014 - 8 reports

Roche-Cipla patent row mediation fails

MUMBAI: Efforts to end the long and bitter patent tussle between domestic pharma company Cipla and multinational Roche over a lung cancer drug have come to a naught, with the Delhi high court-appointed mediator submitting its "failure" report in the ... [Published Times of India - Oct 30 2014]


"We have urged the management to pay wages for all the employees and consider it 'on duty' as it was a very severe cyclone. The other units in the industrial estate such as C P Aqua have followed the same practice. The management has not only rejected our demand but resorted to serving notices on 24 employees from Oct. 26 and stopping them from attending to duties" they said
Zacks’ analyst wrote, "Avanir’s third-quarter of fiscal 2014 loss of $0.08 per share remained unchanged from the year-ago figure and was in line with the Zacks Consensus Estimate. Although revenues increased from the year-ago quarter by 44.9% to $28.6 million, they lagged the Zacks Consensus Estimate of $30 million. We remain concerned about the company’s dependence on Nuedexta for growth. While Avanir is working on developing its pipeline and growing Nuedexta sales, we prefer remaining on the sidelines until we gain visibility on the impact of these efforts. We are initiating coverage on Avanir with a Neutral recommendation."
So I was very pleased to hear Viehbacher also explain, "We are not necessarily seeing it [Afrezza] just to replace injection but [what] we know is that there is often a lost decade that many specialists refer to, and this is a time it often takes for people to move from oral therapies, which have really stopped working and transfer to an injectible product. So we think actually that, even as an add on to oral could be an interesting way to get people on insulin therapy a little bit faster."
Walczak added: "The next step of our work will see how this approach works in other cancer types, and we hope it could ultimately lead to testing this technique in trials to see if it can help patients."

More Content

All (33164) | News (32877) | Reports (1) | Blogs (1) | Audio/Video (0) | Fact Sheets (0) | Press Releases (16)
sort by: Date | Relevance
Aurobindo Pharma employees stage demo [Published Hindu Business Line - 10 mins ago]
Update: GSK Starts Promoting Theravance Drugs M... [Published Seeking Alpha - 19 mins ago]
Weekly Pharma Manufacturing News Roundup — Octo... [Published Pharmaceutical Online - 28 mins ago]
Avanir Pharmaceuticals Given “Neutral” Rating a... [Published American Banking News - 31 mins ago]
Aegerion Pharmaceuticals Downgraded by Deutsche... [Published American Banking News - 31 mins ago]
AstraZeneca plc’s Buy Rating Reiterated at Citi... [Published American Banking News - 32 mins ago]
Retired Eli Lilly exec finds new niche as YourE... [Published Indianapolis Star - 39 mins ago]
Cancer drug fund policy will be reviewed [Published Isle of Man Newspapers - 52 mins ago]
Broad Institute and University of California Te... [Published Targeted News Service - 54 mins ago]
Biotech Manufacturing Center of Texas celebrate... [Published Athens Daily Review - 56 mins ago]
Dr. Falk Pharma GmbH Enrolls First Patients int... [Published Technology Networks - 1 hour ago]
News From Sanofi About MannKind's Afrezza And I... [Published Seeking Alpha - 1 hour ago]
Trevena, Inc. - Product Pipeline Review - 2014 [Published - 1 hour ago]
Celgene Corp (CELG: NAS): Analytics, Extensive ... [Published - 1 hour ago]
Thumb up: Center for Diseases of Aging [Published TCPalm - 1 hour ago]
KAPL to recruit for 36 posts: Apply before Nov 12 [Published India Today - 1 hour ago]
Nurburgring sold to Russian pharmaceutical bill... [Published Car Advice - 1 hour ago]
Teachers, Govt Disagree Over Unpaid Salaries, B... [Published The Guardian Nigeria - 1 hour ago]
KAPL to recruit Assistant General Manager: Appl... [Published India Today - 2 hours ago]
Indian Oil Corporation Limited hiring for 23 posts [Published India Today - 2 hours ago]
Drugs to abet cancer cells suicide found [Published - 2 hours ago]
Research study says long term shift work links ... [Published PharmaBiz - 3 hours ago]
India is in a sweet spot; bullish on IT, pharma... [Published Economic Times - 3 hours ago]
Enhancing Pharmaceutical and Patient Care Servi... [Published VAR India - 3 hours ago]
Amgen Wall Street reacts positively as more lay... [Published - 3 hours ago]
Teva Beats Q3 Earnings Expectations Updates Out... [Published - 3 hours ago]
China launches erectile dysfunction drug less t... [Published Business Standard India - 3 hours ago]
Winter Launch Party for Small Businesses [Published BioSpace - 4 hours ago]
Buyers Can Capitalize As Sellers Lose Confidence [Published BioSpace - 4 hours ago]
The Changing Landscape of Branding Pharmaceutic... [Published Pharmaceutical Executive - 4 hours ago]
1 2 3 4 5 6 7 8 9 10 ...
In Focus
Content Volume
Document Volume


sort by: Date | Relevance
From Sprint And TechStars To The FDA, A Look At... [Published TechCrunch - Oct 10 2013]
The health-care industry in the U.S. is broken, and considering the industry itself represents some 18 percent of the U.S. economy, it’s a sizable problem. While other sectors have begun to adapt, health care has managed to resist change — particularly ...

Press Releases

sort by: Date | Relevance
Using genomics to make personalized, safer medi... [Published PR Newswire - Feb 03 2014]
Endo Completes Acquisition of Specialty Generic... [Published PR Newswire - Feb 03 2014]
10 Reasons Why Biometric Exit May Advance in 2014 [Published PR Newswire - Feb 03 2014]
Regado Biosciences Announces $20 Million Privat... [Published PR Newswire - Jan 31 2014]
Novo Nordisk Promotes Eddie Williams to Senior ... [Published PR Newswire - Jan 30 2014]
1 2 3 4
Contact Us

Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.